Salvat Laboratories Submits NDA for First Ocular Corticosteroid Nanoemulsion

Salvat Laboratories has submitted the NDA documentation for a new drug application to the FDA for approval of Clobetasol, the first ocular corticosteroid formulated in a nanoemulsion for inflammation and pain in patients undergoing eye surgery.

Salvat Laboratories Submits NDA for First Ocular Corticosteroid Nanoemulsion
November 03, 2022
More